Neupogen
Company: Amgen
Approval Status: Approval April 1998
Treatment for: slow white blood cell recovery following chemotherapy
Areas: Hematology; Oncology
General Information
Other Useful Resources
Neupogen has been approved for its fifth indication: to reduce the time to neutrophil recovery and the duration of fever following chemotherapy treatment in patients being treated for acute myeologenous leukemia. Patients with this type of leukemia can now receive Neupogen to improve their ability to tolerate essential chemotherapy treatments.
The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
